Briefing Book for Health Canada and CDA-AMC Parallel Scientific Advice

[Month, Day, Year]

CONFIDENTIAL

**Table of Contents**

[Tables and Figures 4](#_Toc461625049)

[Annexes 5](#_Toc461625050)

[Abbreviations 6](#_Toc461625051)

[1. Rationale for Seeking Advice 7](#_Toc461625052)

[2. Name or Code Name Product 7](#_Toc461625053)

[3. Background Information 8](#_Toc461625054)

[3.1 Overview of the Disease 8](#_Toc461625055)

[3.2 Treatment Options and Relevant Guidelines 8](#_Toc461625056)

[3.3 Current Unmet Need 8](#_Toc461625057)

[3.4 Regulatory Scientific Advice *(Provide date in format Month, Day, Year.)* 8](#_Toc461625058)

[3.5 Health Technology Assessment Scientific Advice/Early Dialogues   
 *(Provide date in format Month, Day, Year.)* 8](#_Toc461625059)

[4. Data Currently Available on the Product 9](#_Toc461625060)

[4.1 Mode of Action or Pharmacological Class 9](#_Toc461625061)

[4.2 Proposed Dosing Regimen and Route Administration 9](#_Toc461625062)

[4.3 Indication and Target Population 9](#_Toc461625063)

[4.4 Regulatory Status 9](#_Toc461625064)

[4.5 Summary of Patient Engagement (If Available) 9](#_Toc461625065)

[4.6 Clinical Data Available to Date 9](#_Toc461625066)

[5. Product Value Proposition 10](#_Toc461625067)

[6. Proposed Clinical Development Program 11](#_Toc461625068)

[7. Proposed Economic Analysis 12](#_Toc461625069)

[8. Questions and Applicant’s Position 13](#_Toc461625070)

[8.1 Questions on the Proposed Clinical Evaluation 13](#_Toc461625071)

[Question 1: 13](#_Toc461625072)

[Question 2: 13](#_Toc461625073)

[8.2 Questions on the Proposed Clinical Evaluation 13](#_Toc461625074)

[Question 3: 13](#_Toc461625075)

[Question 4: 13](#_Toc461625076)

[References 14](#_Toc461625077)

# Tables and Figures

# Annexes

(*This may include additional Annexes for Health Canada e.g., preclinical information)*

# Abbreviations

|  |  |
| --- | --- |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |

# 1. Rationale for Seeking Advice

[Response]

# 

# 2. Name or Code Name Product

[Response]

# 

# 3. Background Information

## 3.1 Overview of the Disease

[Response]

## 3.2 Treatment Options and Relevant Guidelines

[Response]

## 3.3 Current Unmet Need

[Response]

## 3.4 Regulatory Scientific Advice *(Provide date in format Month, Day, Year.)*

|  |  |  |
| --- | --- | --- |
| Agency | Date/Expected Date | Minutes Attached (Y/N) |
| Health Canada |  |  |
| FDA |  |  |
| EMA |  |  |

FDA = Food and Drug Administration (US); EMA = European Medicines Agency; Y/N = yes/no.

## 3.5 Health Technology Assessment Scientific Advice/Early Dialogues *(Provide date in format Month, Day, Year.)*

|  |  |
| --- | --- |
| Country/Agency | Date/Expected Date |
|  |  |
|  |  |
|  |  |

# 4. Data Currently Available on the Product

## 4.1 Mode of Action or Pharmacological Class

[Response]

## 4.2 Proposed Dosing Regimen and Route Administration

[Response]

## 4.3 Indication and Target Population

[Response]

## 4.4 Regulatory Status

(*When is marketing authorization expected? Does the product have marketing authorization in other indications? Please provide date or expected date in format Month, Day, Year, or indicate N/A for not applicable. You may add additional rows to this table for more indications, as needed. Delete rows if they are not required.*)

|  |  |  |  |
| --- | --- | --- | --- |
| Indication | Health Canada | EMA | FDA |
| [Intended indication] |  |  |  |
| [Other indication #1] |  |  |  |
| [Other indication #2] |  |  |  |

FDA = Food and Drug Administration (US); EMA = European Medicines Agency.

## 4.5 Summary of Patient Engagement (If Available)

[Response]

## 4.6 Clinical Data Available to Date

(Insert relevant subsections, as required.)

[Response]

# 5. Product Value Proposition

[Response]

# 6. Proposed Clinical Development Program

(Insert relevant subsections, as required.)

[Response]

# 7. Proposed Economic Analysis

*(If appropriate, your response may indicate that background on the proposed economic analysis is not provided, as economic questions have not been included in the* Briefing Book*.)*

[Response]

# 8. Questions and Applicant’s Position

## 8.1 Questions on the Proposed Clinical Evaluation

### Question 1:

[Applicant’s position]

*(Please note that questions posed should be as specific as possible, with a detailed rationale for the approach proposed. Questions should be posed to both Health Canada and CDA-AMC.Up to two questions each can be posed specifically to Health Canada or CDA-AMC)*

### Question 2:

[Applicant’s position]

*(Insert additional questions here.)*

## 8.2 Questions on the Proposed Economic Evaluation

### Question 3:

[Applicant’s position]

### Question 4:

[Applicant’s position]

*(Insert additional questions here.)*

# References

1. abc
2. abc